Compare Apple Inc (AAPL) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Quest Diagnostics Inc — how do they compare? Apple Inc trades at $314.68 (market cap $4.56T), while Quest Diagnostics Inc trades at $208.33 (market cap $23.51B). The key difference: Apple Inc is far larger — about 194× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| AAPL | DGX | |
|---|---|---|
Market Cap | $4.56T | $23.51B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $216.02 |
52-Week Low | $202.38 | $166.42 |
Enterprise Value | $4.58T | $29.52B |
Dividend Yield | 0.35% | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $314.13, up 0.47% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, beating earnings estimates in recent quarters. Analyst consensus is bullish with a $329.62 price target, though valuation ratios like P/E of 37.61 and P/B of 42.85 suggest premium pricing. Recent news highlights AI potential via a partnership with Alphabet's Gemini and ongoing retail adjustments.
Outlook remains positive driven by earnings growth and AI integration, but risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny. The stock offers stability with consistent cash flow and dividend payments, yet investors should weigh premium multiples against growth sustainability in a challenging macro environment.
Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.
DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
